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Bleeding, Blood Transfusion, and Increased
Mortality After Percutaneous Coronary Intervention
Implications for Contemporary Practice
Brendan J. Doyle, MB, BCH,* Charanjit S. Rihal, MD, MBA,* Dennis A. Gastineau, MD,†
David R. Holmes, JR, MD†
Rochester, Minnesota
Advances in percutaneous coronary intervention (PCI) during the past decade have led to more widespread use
of these procedures in older and sicker patients. Refinement of periprocedural antithrombotic therapy has
played a particularly important role in reducing ischemic complications to very low levels in routine practice. Al-
though the use of more powerful antiplatelet agents has been associated with increased risk of bleeding (espe-
cially among the elderly and patients with serious comorbidities), such complications have traditionally been
viewed as benign in nature. Recent studies, however, have identified major bleeding after PCI as an important
predictor of increased mortality. Whether this relationship between bleeding and risk of death is cause-and-
effect, or merely an association based on shared risk factors, remains unclear. In this review, we examine the
basis for a possible causal link between post-PCI bleeding and subsequent mortality. Possible mechanisms un-
derpinning such a link are discussed, including a potential adverse role for blood transfusion in this setting.
A framework for further clinical evaluation of this issue is presented. (J Am Coll Cardiol 2009;53:2019–27)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.073o
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iecent studies have linked major bleeding after percutane-
us coronary intervention (PCI) with increased mortality
1–8). The nature of this relationship, however, and its
mplications for clinical practice remain unclear. It is pos-
ible that bleeding may simply be a surrogate for high-risk
atients, because those patients at increased risk for bleeding
omplications (such as the elderly) are also at increased risk
f death after PCI (9). It is also possible that bleeding may
e an important, but until now overlooked, cause of excess
ortality. Support for this hypothesis is provided by accu-
ulating mechanistic data that implicates direct and indi-
ect effects of bleeding on subsequent adverse events (10,11).
rowing suspicion also has focused on potentially harmful
ffects of red blood cell (RBC) transfusion (1,5,6,12,13).
The unraveling this complex relationship among bleed-
ng, blood transfusion, and excess mortality is not merely of
cademic interest. In current practice, the risk for major
leeding is dependent not only on patient characteristics (6)
ut also to a large extent on choice of vascular access strategy
radial vs. femoral) (14), and to a lesser extent on the choice
f an antithrombotic regimen (4,15). Physician preference
n these matters may be heavily influenced by the perception
rom the *Division of Cardiovascular Diseases and †Division of Hematology and
ransfusion Medicine, Department of Internal Medicine, Mayo Clinic College of
edicine, Rochester, Minnesota.b
Manuscript received June 27, 2008; revised manuscript received December 15,
008, accepted December 15, 2008.f bleeding as a nuisance complication, rather than a life-
hreatening one. Furthermore, the inclusion of bleeding as a
art of the primary end point in some recent PCI trials is a
ignificant development, drawing equivalence between this
omplication and other major adverse events (such as peripro-
edural myocardial infarction) in the evaluation of novel
herapeutics (3,15). The validity of this approach that com-
ines efficacy and safety end points is debated (16). In this
eview, we examine the evidence supporting a causal link
etween major bleeding and excess mortality in patients un-
ergoing PCI, consider the implications of these data for
ontemporary clinical practice, and propose a framework for
urther evaluation of this controversial issue.
mpact of Major Bleeding and
lood Transfusion on Mortality After PCI
tudies that have examined the impact of major bleeding on
ortality among patients undergoing PCI are summarized in
able 1. Data from more than 90,000 patients are now
vailable, derived from a combination of unselected “real-
orld” cohorts (1,5–8) and randomized trial populations
2–4). Although bleeding definitions and patient characteris-
ics varied, a consistent finding of increased mortality among
atients who experience major bleeding has emerged.
The first study to address this question revealed markedly
ncreased mortality among unselected patients with major
leeding (7.5% in-hospital mortality vs. 0.6% for patients with
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Bleeding, Blood Transfusion, and PCI June 2, 2009:2019–27no bleeding; p  0.001) (1). After
adjustment for differences in pa-
tient characteristics, major bleed-
ing was associated with an odds
ratio of 3.5 for in-hospital mortal-
ity (p  0.0001) (1). Data from
the REPLACE-2 (Randomized
Evaluation in PCI Linking Angio-
max to Reduced Clinical Events)
trial (comparing bivalirudin with
unfractionated heparin plus glyco-
protein IIb/IIIa inhibitors in pa-
tients undergoing PCI) extended
hese findings by associating major bleeding with an adjusted
dds ratio of 3.53 for 1-year mortality (2). Of note, this hazard
as greater than that observed between in-hospital myocardial
nfarction (MI) and 1-year mortality.
Similar findings have been published by other investi-
ators (3–5,7). In these analyses, both access site and
emote (e.g., intracranial) bleeding events were grouped
ogether in the definition of major bleeding. This has led
o some ambiguity regarding the importance of access-
elated bleeding. Hemorrhage at sites such as the intra-
ranial space or the gastrointestinal tract are well recog-
ized as potentially fatal events. Femoral bleeding
omplications have, in contrast, traditionally been viewed
s benign and, as a result, there has been little impetus to
onsider more widespread use of the radial approach as
art of a strategy to reduce overall rates of fatal bleeding
omplications.
However, the authors of an analysis of 17,901 patients
ho underwent PCI between 1995 and 2006 found that
ajor femoral bleeding complications (including major
ematoma, external bleeding, and retroperitoneal bleed-
ng) also were associated with decreased long-term sur-
ival, driven by a marked increase in 30-day mortality (6).
his association persisted after correction for multiple
redictors of PCI-related mortality, with a 30-day ad-
usted hazard ratio of 9.96 (95% confidence interval: 6.94
o 14.3, p  0.001) (6). Similar findings have been
tudies of the Impact of Major Bleeding on Mortality After PCI
Table 1 Studies of the Impact of Major Bleeding on Mortality A
Author/Study
(Ref. #) Patients (n) Patient Population STEMI Included?
Kinnaird et al. (1) 10,974 Unselected Yes
REPLACE-2 (2) 6,001 Elective and ‘urgent’ PCI No
Ndrepepa et al. (3) 5,348 Elective, ACS No
ACUITY (4) 13,819 ACS only No
Kim et al. (5) 6,799 Unselected Yes
Doyle et al. (6) 17,901 Unselected Yes
GRACE registry (7)* 24,045 ACS Yes
Yatskar et al. (8) 6,656 Unselected Yes
31% of patients in the GRACE (Global Registry of Acute Coronary Events) registry (7) underwent P
emoral bleeding complications only; Yatsker et al. (8) studied hematoma requiring blood transfu
Abbreviations
and Acronyms
MI  myocardial infarction
NO  nitric oxide
PAI  plasminogen
activator inhibitor
PCI  percutaneous
coronary intervention
RBC  red blood cell(s)
TRIM  transfusion-related
immunomodulationACUITY Acute Catheterization and Urgent Intervention Triage strategY; HR hazard ratio; OR odds r
ngiomax to Reduced Clinical Events; RR  relative risk; STEMI  ST-segment elevation myocardial infaublished by Yatskar et al. (8), suggesting that major
emoral bleeding should not be dismissed as a trivial
omplication of PCI.
Emerging evidence suggests that transfusion may be
ssociated with risks over and above usual concerns
egarding microbial transmission and acute antigen-
ntibody reactions (17). A number of studies have exam-
ned the impact of RBC transfusion on long-term out-
omes after PCI. The findings are summarized in Table
. Among high-risk patients with anemia (12) or severe
leeding (5), blood transfusion was required in 20%
nd was associated with increased in-hospital mortality
adjusted odds ratio: 2.02, p  0.001) (12) and increased
-year mortality (relative risk: 2.03, p  0.028) (5).
mong unselected patients blood transfusion was re-
uired in approximately 5% and was independently asso-
iated with increased mortality (1,6). A case-control
tudy of 146 transfused patients versus 292 nontransfused
atients with major bleeding found an independent
ssociation between blood transfusion and increased
-year mortality (relative risk: 2.42, p  0.0045) (5).
Collectively, these studies demonstrate a robust association
mong major bleeding, blood transfusion, and increased mor-
ality in patients undergoing PCI and are in keeping with
eports of decreased survival among patients with acute coro-
ary syndromes who experience major bleeding (10) or require
lood transfusion (18,19). It is important to emphasize, how-
ver, that none of these studies can establish a causal connec-
ion between bleeding events (or blood transfusion) and in-
reased risk of death after PCI. Although the relationship
etween bleeding and mortality is described in several studies
s an independent one, many of the correlates of bleeding (such
s advanced age and renal failure) are themselves associated
ith mortality. No amount of statistical adjustment can pro-
ide certainty of a cause-and-effect relationship when there is
his degree of correlation (16). As a result, resolving the
uestion of association versus causality has been a tremendous
hallenge, but emerging mechanistic data have begun to
nlighten the debate.
PCI
ition
Frequency of Blood
Transfusion (%)
Impact of Bleeding on Mortality
[95% Confidence Interval] p Value
5.4 30-day adjusted OR: 3.5 [1.9–6.7] 0.0001
col† 3.2 1-year adjusted OR: 2.66 [1.44–4.92] 0.002
4.0 1-year adjusted HR: 2.96 [1.96–4.48] 0.0001
col† 4.7 30-day OR: 7.55 [4.68–12.18] 0.0001
col† 8.0 1-year RR: 2.03 (transfused patients) 0.0028
col† 4.8 30-day adjusted HR: 9.96 [6.94–14.3] 0.0001
col† 3.9 In-hospital adjusted OR: 1.64 [1.18–2.28] 0.0001
col† 1.8 In-hospital adjusted OR: 3.59 [1.66–7.77] 0.001
1-year adjusted HR: 1.65 [1.01–2.70] 0.048
tocol definitions of major bleeding varied between these studies (8). Note: Doyle et al. (6) studied
ly.fter
Defin
TIMI
Proto
TIMI
Proto
Proto
Proto
Proto
Proto
CI. †Pro
sion onatio; PCI percutaneous coronary intervention; REPLACE Randomized Evaluation in PCI Linking
rction; TIMI  Thrombolysis In Myocardial Infarction.
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June 2, 2009:2019–27 Bleeding, Blood Transfusion, and PCIechanisms Linking
leeding With Excess Mortality
he biological impact of bleeding after PCI is likely to be
ultifaceted (Fig. 1). The location (intracranial) or
orrential nature of the hemorrhage (gastrointestinal,
tudies of the Impact of Blood Transfusion on Mortality After PCI
Table 2 Studies of the Impact of Blood Transfusion on Mortalit
Author (Ref. #) Patients (n) Patient Population STEMI Included?
Jani et al. (12) 4,623 Anemic patients with MI Yes
Doyle et al. (6) 17,901 Unselected Yes
Kinnaird et al. (1) 10,974 Unselected Yes
Kim et al. (5)* 567* Severe bleeding Yes
Chase et al. (13) 38,872 Unselected Yes
A subgroup (n  567) of the overall cohort (n  6,799) that had “severe” bleeding was studied
MI  myocardial infarction; other abbreviations as in Table 1.
Figure 1 Possible Mechanisms Linking Post-Percutaneous Coro
Figure provided by the Mayo Clinic ©2008.etroperitoneal) may result in death, regardless of any
revious cardiac procedure. However, other consequences
f bleeding may have specific detrimental effects in
atients who have recently undergone coronary interven-
ion and may offer an explanation for the association
er PCI
quency of Blood
ransfusion (%)
Impact of Transfusion on Mortality
[95% Confidence Interval] p Value
22.3 In-hospital, adjusted OR: 2.02 [1.47–2.79] 0.0001
6.8 30 days, 1–2 U adjusted HR: 8.9 [6.3–12.6] 0.0001
3 U adjusted HR: 18.1 [13.7–24] 0.0001
5.4 1 year, OR per unit transfused: 1.47 [1.36–1.55] 0.0001
25.7 1 year, RR: 2.03 0.0028
3.5 30-day adjusted OR: 4.01 [3.08–5.22] 0.0001
1-year adjusted OR: 3.58 [2.94–4.36] 0.0001
nalysis.
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Bleeding, Blood Transfusion, and PCI June 2, 2009:2019–27etween femoral bleeding complications and mortality
hat is more difficult to comprehend.
Interactions between activated platelets and the clotting
ascade produce a rapid hemostatic response at the site of
ascular injury. Systemic amplification of this localized
esponse is prevented by a number of mechanisms, includ-
ng control of the activated procoagulants and platelets by
ntithrombotic pathways (20). These antithrombotic path-
ays are predominantly active within vascular endothelial
ells (20), but little is known about the function of these
athways in patients with cardiovascular disease. Deficiency
f such antithrombotic protective mechanisms (in tandem
ith systemic endothelial dysfunction) could lead to a
ypercoagulable state induced by bleeding, which would
ose obvious risks to the patient who had recently under-
one PCI.
Furthermore, experimental data suggest that increased
ynthesis and release of erythropoietin in response to anemia
aused by bleeding might sustain a systemic prothrombotic
tate beyond the acute phase, by causing platelet activation
nd inducing plasminogen activator inhibitor-1 (a proco-
gulant cytokine) (21,22). Treatment with erythropoietin
as been associated with increased risk of thrombosis in
ritical care patients (23). Finally, aspirin, clopidogrel, or
ther antithrombotic medication may have to be discontin-
ed after a major bleeding event, thus increasing the risk for
tent thrombosis, a complication that frequently is fatal
24–26).
The significance of these issues in everyday clinical
ractice is difficult to quantify, but recent data have con-
rmed an increased risk of acute ischemic events after major
leeding suggesting that the hypothetical concerns de-
cribed previously may be justified (10). Definitively resolv-
ng the issue of causality will be a significant challenge.
lthough it is impossible to randomly allocate patients to
leeding, a randomized comparison of transradial versus
ransfemoral PCI with mortality as a primary end point may
e a clinically relevant way to address the issue. Many small
Figure 2 Impact of Storage on RBCs and Tissue Oxygen Delive
DPG  diphosphoglycerate; Hb  hemoglobin; NO  nitric oxide; RBC  red bloodtudies comparing these access strategies have already been
ublished and presented (14), but there are multiple con-
ounding factors that make interpretation difficult. It is
ossible that patients selected for a radial approach may be
ery different in terms of baseline demographics and risk
rofiles that are hard to adjust for. The publication of data
rom recent randomized PCI trials analyzing outcomes
mong subgroups of patients treated using a radial versus
emoral approach are eagerly awaited and may provide the
latform for a dedicated access strategy trial with mortality
s a primary end point.
echanisms Linking Blood
ransfusion With Excess Mortality
mpairment of oxygen delivery. Increasing hemoglobin
evel via transfusion increases oxygen delivery (27–29), but
easures of tissue oxygenation either decrease or do not
hange (27,28,30,31). The reason for this paradox (greater
xygen delivery but no increase in tissue use) is unclear (18).
Stored RBCs are low in 2,3-diphosphoglyceric acid
2,3-DPG); therefore, the hemoglobin has high oxygen
ffinity (i.e., will tend not to release oxygen to the tissues).
raditionally, this finding been regarded as the pre-eminent
echanism underlying reduced tissue extraction of oxygen
rom the circulation after blood transfusion (32). However,
,3-DPG levels partially recover within several hours after
ransfusion, and the results of experimental studies now
ndicate that the physiologic impact of 2,3-DPG depletion
ay have been overstated (33–35). Recent data suggest that
ther structural and biochemical changes that occur in
BCs during storage might have a greater impact on their
unction in vivo (Fig. 2).
Normally, erythrocytes have a flexible membrane and can
eversibly alter their biconcave, discoid shape, thus allowing
hem to pass through capillaries smaller in diameter (2 to 6
m) than RBCs (8 m). This property of red cells also
cts as an in vivo quality control marker, whereby older, less
SNO  S-nitrosothiol.ry
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June 2, 2009:2019–27 Bleeding, Blood Transfusion, and PCIompliant cells are filtered in the spleen and cleared by
hagocytosis from the circulation (36). During storage,
here is a significant decrease in the deformability of RBCs.
ther hemorheological alterations also have been docu-
ented, such as changes in RBC shape, decreased surface/
olume ratio, increased mean hemoglobin concentration
nd osmotic fragility, increased aggregability, and intracel-
ular viscosity (36–38). Together, these factors may predis-
ose to “plugging” of transfused cells at the microvascular
evel, leading to tissue ischemia. It is reasonable to assume
hat vascular beds already compromised by microvascular
ysfunction or obstruction (such as acutely infarcted myo-
ardium) may be particularly vulnerable in this respect.
Interest also has focused on the transport of nitric
xide (NO) by RBCs. Nitric oxide produced by the
ascular endothelium may be bound by erythrocytes in
rotected form as an S-nitrosothiol (SNO) on the highly
onserved hemoglobin -93 Cys residue (39,40). Upon
elease of oxygen, SNO-hemoglobin may dispense NO
ioactivity to microvascular cells, physiologically cou-
ling hemoglobin deoxygenation to vasodilation (39).
his elegant mechanism facilitates increases in regional
lood flow in zones of hypoxia and, intriguingly, may
nable NO bioactivity to be imported from a healthy
ascular bed to one that is compromised by endothelial
ysfunction (as would pertain in the coronary circulation
f patients undergoing PCI).
Recent data indicate that this biochemical function is
ignificantly disrupted by storage of RBCs, with a rapid
ecrease in SNO-hemoglobin concentrations to 30% of
nitial levels observed within 1 day of storage (20% within
week) (41). It is important to note that it takes 48 h from
he time of donation to complete the required testing and
reparation of a unit of RBCs for transfusion. Hypoxic
asodilation by banked RBCs correlated strongly with the
mount of SNO-hemoglobin, underscoring the physiologic
ignificance of the findings (41).
rothrombotic effects. The transfusion of blood products
as been associated with an acute platelet release of CD40
igand (42). Transfusion also is associated with increased
xposure to another procoagulant protein, plasminogen
ctivator inhibitor (PAI)-1. There is a 3- to 6-fold increase
n PAI-1 content of packed RBCs stored for greater than 35
ays (43), and serum levels of PAI-1 increase after alloge-
eic blood transfusion (44). Adenosine diphosphate, a
ell-recognized mediator of platelet activation, might also
articipate in transfusion-related vascular thrombosis.
denosine diphosphate is released from activated platelets
nd damaged endothelial cells and is also released by
rythrocytes in stored blood (42). Finally, free NO acts not
nly as a potent vasodilator but also as an inhibitor of
latelet activation (42). Deficiencies of NO transport and
elease by stored RBCs may therefore not only impact
dversely on regional blood flow in zones of hypoxia but also
n risk for thrombosis at sites of endothelial dysfunction. ather adverse effects of blood transfusion. Transfusion-
elated immunomodulation (TRIM) is an immunosuppres-
ive, or in some cases proinflammatory, effect of blood
ransfusion that may contribute to adverse outcomes among
ecipients of blood (42,45). The proposed mechanism for
RIM is induced alterations of endogenous cytokine levels
n the recipient that participate in protective inflamma-
ory responses to pathogens. Infusion of bioactive sub-
tances such as histamines, cytokines, lipids, microparticles
cell membrane fragments), and HLA class 1 antigens that
ccumulate in blood during storage may play a role (45).
uch derangement of the immune system may predispose to
nfections and, driven by augmented humoral responses,
cute lung injury.
The specific effects of this phenomenon on plaque biol-
gy, thrombosis, and microvascular function are as yet
ndefined, but given the inflammatory nature of atheroscle-
osis, the potential for such interplay is of obvious concern.
inally, severe hemolytic reactions and the consequences of
arge-volume transfusion (such as coagulopathy and electro-
yte disturbance) also may increase mortality associated with
lood transfusion (46), although these effects are not specific
o the post-PCI population.
uration of storage of transfused blood. Many of the
forementioned concerns ultimately appear to hinge upon
he duration that blood is kept in storage before use. The
ood and Drug Administration allows packed red cells to be
tored for up to 42 days, allowing blood centers the
exibility to manage this scarce resource but also influencing
he quality of blood that is transfused. Whether clinical
utcomes are adversely affected by longer storage, however,
s still uncertain.
In a recent study by Koch et al. (47), patients undergoing
ardiac surgery who received older (14 days) blood had
reater in-hospital mortality than patients receiving newer
lood (2.8% vs. 1.7%, p  0.004). Patients who were given
lder blood were also at greater risk for a composite
utcome of multiple serious adverse events (such as pro-
onged ventilatory support, renal failure, sepsis, or multior-
an failure). At 1 year, mortality remained significantly
ower in patients given newer blood (7.4% vs. 11.0%, p 
.001). The results of previous studies evaluating the effect
f storage duration on outcomes have been contradictory
47), possibly relating to small sample size and methodolog-
cal limitations. The sample size in the study by Koch et al.
47) was large and, notably, the analysis was restricted to
atients given only newer blood or only older blood,
nabling the effect of duration of storage on outcomes to be
etter characterized. Limitations of the study include po-
entially important differences in baseline characteristics
etween the 2 groups (including worse left ventricular
ystolic function and greater prevalence of peripheral vascu-
ar disease in the “old-blood” group). Furthermore, no
ttempt was made to correct for type of transfusion or use of
dditional blood products; transfusion of unmatched blood
nd use of fresh-frozen plasma or platelets may identify a
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Bleeding, Blood Transfusion, and PCI June 2, 2009:2019–27opulation at greater risk for bad outcomes that may not
elate to the RBC transfusion. Nevertheless, the results of
he study raise the possibility of clinically meaningful harm
ssociated with transfusion of blood that has been stored for
onger than 14 days.
No data are available currently regarding the impact of
torage duration on outcomes for patients who require
ransfusion after PCI. There are, however, reasonable
rounds for concern that administration of blood that has
een stored for longer than 14 days also may be associated
ith worse outcomes for PCI patients, given the similarities
n clinical characteristics with cardiac surgery patients.
ndeed, SNO-hemoglobin levels (and their physiologic
orrelate RBC-dependent vasodilation) become depressed
ithin days of collection (41), suggesting that even “fresh”
lood may have developed adverse biological characteristics
hat may have clinical relevance.
mplications for clinical practice. The concerns outlined
erein should not lead clinicians to withhold blood trans-
usion when it is clearly indicated (i.e., severe anemia
ausing symptoms or other evidence of ischemia, especially
or patients who exhibit signs of oxygen-supply depen-
ency) (48–50). Efforts to reduce the impact of bleeding
omplications on the PCI population should rather focus
n: 1) the identification of measures to decrease the inci-
ence of bleeding complications without increasing risk for
schemic events; and 2) the development of strategies for
ore targeted and safer use of blood transfusion.
educing bleeding complications. A prognostic risk score
or major bleeding in patients undergoing PCI via the
emoral approach has been published, allowing the identi-
cation of high-risk patients before the procedure (51).
even variables were proposed based on an analysis of
leeding events from the REPLACE-2 trial: age55 years,
emale sex, estimated glomerular filtration rate 60 ml/
in/1.73 m2, pre-existing anemia, use of low-molecular-
eight heparin within 48 h before PCI, use of glycoprotein
Ib/IIIa inhibitors, and the use of the intra-aortic balloon
ump (51). Weighting for each was assigned by the use of
ifferent integer scores, with a total score of 10 associated
ith a major bleeding risk of 5%. Although this risk-
coring system remains to be validated in real-world co-
orts, such a tool may help inform decisions regarding
nitial management strategy (for patients with borderline
ndications for PCI) and enable the interventionalist to
ailor the strategic approach according to bleeding risk for
hose who do proceed with intervention.
The single most effective way for the operator to
educe major bleeding is to use radial rather than femoral
ccess (14). A systematic review of randomized trials
evealed an odds ratio of 0.20 (95% confidence interval:
.09 to 0.42; p  0.0001) for access-site complications
fter radial rather than femoral PCI (14). Furthermore, in
retrospective study of almost 39,000 procedures, trans-
adial PCI was associated with one-half the number of
leeding complications, markedly reduced transfusion tequirements, and lower adjusted 30-day and 1-year
ortality (p  0.001) (13).
Selection bias could certainly account for the finding of
ecreased mortality, as it seems likely that the most complex
ases requiring large devices and hemodynamic support
ould have been performed from the femoral route. How-
ver, it is possible that decreased bleeding complications
and transfusion requirements) also could have contributed,
t least in part, to the finding of lower mortality among
atients treated via the radial artery. It is important to
mphasize that there are no published randomized data to
ndicate that use of the radial approach is associated with
ower mortality when compared with a femoral approach.
hen femoral access is chosen, the routine use of fluoros-
opy (52) (and perhaps ultrasound) to guide puncture may
educe the incidence of serious complications. Although
ascular closure devices have so far failed to reduce bleeding
omplications (53), it is hoped that further evolution of this
echnology may ultimately achieve this goal.
The selection of periprocedural antithrombotic therapy
lso may influence bleeding risk, with debate focusing
ainly on the choice between bivalirudin and the combi-
ation of heparin with a glycoprotein IIb/IIIa receptor
locker. Although bivalirudin reduces major bleeding in
lective and urgent PCI (15), as well as non–ST-segment
levation acute coronary syndromes (4), some questions
ave remained regarding its efficacy in preventing ischemic
omplications (54). Although there was an excess of isch-
mic events among patients treated with bivalirudin, use of
pre-defined 25% margin for noninferiority combined with
se of a quadruple end point that included major bleeding
vents resulted in no statistically significant difference be-
ween the 2 treatment groups (4,15).
Both the size of the noninferiority margin and use of
ajor bleeding in the combined end point would tend to
ias the results in favor of bivalirudin. Interestingly, patients
ho were pre-treated with clopidogrel and subsequently
eceived bivalirudin in the catheterization laboratory exhib-
ted no excess of ischemic events but did maintain lower
ates of major bleeding (4). The results of the recent
SAR-REACT 3 (Intracoronary Stenting and Antithrom-
otic Regimen: Rapid Early Action for Coronary Treat-
ent 3) trial confirm a reduction in major bleeding with
ivalirudin but no overall impact on mortality (among
atients undergoing PCI who had not presented with MI)
r on the combined end point of death, MI, or target lesion
evascularization (55). In this study the quadruple end
oint, which included major bleeding, also was nonsignifi-
ant, with the favorable effect of bivalirudin on bleeding
eemingly counterbalanced by a small excess of ischemic
vents (55).
Data from the HORIZONS-AMI (Harmonizing Out-
omes With Revascularization and Stents in Acute Myo-
ardial Infarction) study of patients with ST-segment ele-
ation MI undergoing primary PCI has further enlivened
he debate, whereby reduced bleeding was associated with
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June 2, 2009:2019–27 Bleeding, Blood Transfusion, and PCIower all-cause 30-day mortality in patients treated with
ivalirudin (56). The publication of long-term follow-up
rom this cohort is eagerly awaited. Although the weight of
vidence would suggest that bivalirudin is a reasonable
hoice for routine use in the catheterization laboratory, it
ppears that this agent may ultimately prove most useful for
atients at increased risk of major bleeding complications.
efinements in the use of blood transfusion. In addition
o reducing the incidence of major bleeding complications,
efinements in the use of blood transfusion may lead to
etter outcomes for patients undergoing PCI. Appropriate
ndications for transfusion after PCI have not yet been
efined, specifically with regard to the hemoglobin level
bove which the risks of transfusion might outweigh any
enefit. Among patients with critical illness, a randomized
rial has demonstrated that those treated with the use of a
estrictive transfusion policy had better outcomes (when
ompared with a more liberal transfusion policy) (57),
lthough older patients with cardiac disease were high-
ighted as a specific group to whom the findings might not
e applicable (50).
The situation is likely to be even more complex among
atients undergoing PCI, because factors such as clinical
resentation and completeness of revascularization will
robably alter the risk/benefit ratio for transfusion. For
xample, observational data suggest that a more liberal
pproach to blood transfusion in the setting of acute MI
ay be beneficial, although how this strategy interacts with
he approach to revascularization is not entirely clear (48).
Might early and complete revascularization offset the the-
retical need to increase oxygen-carrying capacity through
lood transfusion?)
Pre-emptively targeting patients with anemia may be
nother way to reduce transfusion requirements after PCI.
aseline anemia is associated with increased need for blood
ransfusion and greater mortality after PCI (58,59). Aggres-
ive strategies to increase hemoglobin levels with the use of
ron repletion, erythropoietin, or other disease-specific mea-
ures would probably reduce the need for transfusion by
roviding a greater window of tolerance for bleeding. It is
easonable to assume that such an approach could also
mprove tolerance of myocardial ischemia during long,
omplex cases. Although the value of postponing elective
CI to treat anemia has not yet been tested, given the
requency of this finding in routine clinical practice such a
tudy would clearly be of tremendous interest.
There are ongoing efforts to improve the quality of
ransfused blood through refined harvest and storage
echniques. For example, decreased deformability of
tored RBCs may be ameliorated by correction of intra-
ellular pH and restoration of adenosine triphosphate
evels (36,60). Repletion of SNO-Hb levels during stor-
ge improved the vasodilatory function of RBCs in vivo
41). Reduction of the white blood cell content of stored
lood (leukodepletion) also may contribute to improve-
ents in RBC function and decrease the content of pytokines and inflammatory mediators in stored blood
61– 64). The immune response to TRIM is attenuated
y leukodepletion of blood products before transfusion,
uggesting that either a component or byproduct of donor
eukocytes elicits the recipient response (65).
The age of RBCs at the time of collection might also
ffect the impact of storage time on RBCs. In normal
ircumstances, erythrocytes have a lifespan of approximately
20 days. It would be expected therefore that a unit of blood
ould contain a proportion of cells that are approaching the
nd of their lifespan and may be more prone to storage-
nduced changes than younger cells. In support of this
ypothesis, Sparrow et al. (66) separated old and young
BCs before storage and reported differences in the cell-
urface expression of cell adhesion molecules and glycophorin A.
ith a growing understanding of storage-related hazards
nd the development of assays to measure these, it appears
ikely that quality criteria for RBCs will expand in the future
o include functional biochemical properties in addition to
urrent regulations based on hemolysis and hemoglobin
ass (36).
On the basis of current data, it is our view that use of
rbitrary cutoffs (such as a hemoglobin of8 g/dl) to trigger
ransfusion after PCI should be avoided in most circum-
tances. Risks and potential benefits of transfusion should
e weighed on clinical grounds. Among patients with low
emoglobin who exhibit evidence of ischemia despite suc-
essful revascularization, there is clear potential for blood
ransfusion to have a net beneficial effect. When there is
learly no evidence of ongoing ischemia, and therefore
inimal potential gain, adverse effects of transfusion may be
ore likely to predominate (an exception to this may be the
symptomatic patient who is considered at very high risk for
ebleeding from a noncompressible site, where a greater
eserve of red cell mass may be desirable).
The design of a randomized trial to define the optimal use
f blood transfusion for patients with bleeding after PCI
ould be quite complicated. Most would consider it uneth-
cal to withhold transfusion from a patient with low hemo-
lobin who exhibits clear evidence of ischemia. A study of
ransfusion versus no transfusion for post-PCI bleeding
mong patients who are asymptomatic, however, should not
resent any ethical difficulties and would certainly be of
nterest. The arbitrary hemoglobin threshold for enrollment
ould need to be set quite low (certainly 8 g/dl) to allow
ny potential therapeutic effect of transfusion to emerge.
ecruitment of sufficient patients to complete such a trial
ould be a challenge, but should be possible using a
ulticenter collaborative approach.
onclusions
ccumulating clinical and experimental data establish a
trong association between major bleeding, blood transfu-
ion, and the risk of death after PCI. It remains to be
roven, however, that strategies to reduce bleeding and/or
b
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n addition, despite frequent use of blood transfusions in
atients undergoing PCI, important questions regarding
ppropriate transfusion thresholds and the importance of
he age of stored blood remain unanswered. These issues
eed to be addressed as a priority by adequately powered
tudies.
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